

CarThera presents preliminary efficacy data for treating recurrent glioblastoma

04 June 2018 | News

Preliminary data from the first clinical trial of the company's intracranial ultrasound implant, SonoCloud, show a good safety profile and promising trends in overall survival.



CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, has announced the preliminary data of its Phase I/IIa clinical trial (NCT02253212) on ultrasound induced blood-brain barrier (BBB) opening.

Dr. Ahmed Idbaih, principal investigator and neuro-oncologist at AP-HP hospital in Paris, presented preliminary data from a trial involving 21 patients with recurrent glioblastoma (GBM), who were treated monthly with the SonoCloud device prior to carboplatin chemotherapy. The presentation took place at the McCormick Place Convention Center in Chicago, Illinois on June 2 during a session on Central Nervous System Tumors at the American Society of Clinical Oncology (ASCO).

The BBB prevents the passage of most drugs from the blood to the brain and may be responsible for the limited efficacy of current chemotherapies in GBM patients. To tackle this problem, Pr. Alexandre Carpentier, a French neurosurgeon at AP-HP and founder of CarThera, developed SonoCloud, a low-intensity pulsed ultrasound device that temporarily increases the permeability of the BBB and enhances the delivery of therapeutic molecules to the brain.

“Our mission is to improve the prognosis of patients with brain diseases by increasing the permeability of cerebral blood vessels to allow therapeutic molecules such as antibodies, pathway inhibitors, chemotherapies or enzymes to reach effective concentrations in the brain,” said Frederic Sottolini, CEO of CarThera.

In preliminary analysis of the data from 21 GBM patients who received 65 SonoCloud treatments, the investigators observed a good safety profile and trends in improvement of Progression Free and Overall Survival. OS was increased from 8.5 to 12.9 months in patients who had SonoCloud-induced BBB opening.

“We are excited to share promising preliminary data from our clinical trial at the ASCO annual meeting attended by more than 32,000 oncology professionals from around the world,” said Dr. Idbaih. “The sonication of larger volumes of brain in recurrent GBM will be investigated in a future trial and may further enhance the observed effectiveness of this new treatment modality.”

“Preliminary efficacy results presented by Dr. Idbaih at the annual ASCO meeting demonstrate the proof of concept of our first-in-class solution to enhance delivery of therapeutic agents in the brain. The increase in survival observed in GBM patients paves the way for the combination of the SonoCloud device with different agents for treating various brain disorders, such as cancers and neurodegenerative diseases,” said Frederic Sottolini.

According to the company’s estimates, each year 250,000 patients worldwide are diagnosed with brain tumors. The SonoCloud could benefit these patients as well as millions more with debilitating brain disorders.